Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432195 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations
A Phase 1 study, sponsored by Corium.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03432195 is a Phase 1 study that has completed, run by Corium. The registered enrollment target is 66 participants.
The verdict
NCT03432195, a Phase 1 study, has completed, sponsored by Corium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
A Phase 1, Crossover Study to Evaluate the Pharmacokinetics of Corplex™ Donepezil 10 mg Transdermal Delivery System Applied to Different Body Locations
Interventions
- DRUG Donepezil TDS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2018-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03432195
The ClinicalTrials.gov registry entry for NCT03432195 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corium, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Donepezil TDS is the first listed.
NCT03432195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03432195 about?
NCT03432195 is a clinical study titled "A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations". A Phase 1, Crossover Study to Evaluate the Pharmacokinetics of Corplex™ Donepezil 10 mg Transdermal Delivery System Applied to Different Body Locations
What is the current status of trial NCT03432195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2018-01-31. Estimated completion is 2018-06-28.
What interventions are being tested in trial NCT03432195?
The interventions under investigation include: Donepezil TDS (DRUG).
Who is sponsoring clinical trial NCT03432195?
This trial is sponsored by Corium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.